Verrica Pharmaceuticals Inc.
General ticker "VRCA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $62.0M (TTM average)
Verrica Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 25.0%.
Estimated limits based on current volatility of 4.1%: low 5.16$, high 5.60$
Factors to consider:
- Earnings expected soon, date: 2026-08-11 bmo
- Total employees count: 76 (+7.0%) as of 2025
- Top business risk factors: Insufficient capital, Unable to continue as going concern, Product development failure, Regulatory and compliance, Clinical trial failure
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.81$, 10.13$]
- 2026-12-31 to 2027-12-31 estimated range: [3.64$, 9.64$]
Financial Metrics affecting the VRCA estimates:
- Negative: with PPE of -5.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -20.17 <= 0.30
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Negative: negative Net income
- Positive: Inventory ratio change, % of -20.81 <= -0.76
Short-term VRCA quotes
Long-term VRCA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $5.12MM | $7.48MM | $35.33MM |
| Operating Expenses | $70.88MM | $73.40MM | $47.52MM |
| Operating Income | $-65.76MM | $-65.92MM | $-12.19MM |
| Non-Operating Income | $-1.24MM | $-10.66MM | $-5.70MM |
| Interest Expense | $3.96MM | $9.41MM | $7.74MM |
| R&D Expense | $20.30MM | $11.84MM | $8.86MM |
| Income(Loss) | $-67.00MM | $-76.58MM | $-17.89MM |
| Net Income(Loss)* | $-67.00MM | $-76.58MM | $-17.89MM |
| Stockholders Equity | $19.76MM | $-9.86MM | $24.74MM |
| Inventory | $1.02MM | $2.46MM | $2.24MM |
| Assets | $81.60MM | $54.13MM | $47.13MM |
| Operating Cash Flow | $-38.58MM | $-60.93MM | $-17.63MM |
| Capital expenditure | $0.36MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $-0.36MM | $-0.02MM | $0.00MM |
| Financing Cash Flow | $74.21MM | $37.73MM | $1.45MM |
| Earnings Per Share** | $-14.78 | $-14.78 | $-1.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.